People with multiple myeloma who once spent hours connected to an intravenous drip for daratumumab can now receive the same drug through a brief injection under the skin. The shift from IV to subcutaneous delivery was backed by a phase 3 non-inferiority trial and subsequent regulatory approvals on both sides of the Atlantic, and it has reshaped how and where patients receive one of the most widely used myeloma therapies. The practical difference is stark: what formerly required extended clinic time, premedication protocols, and close monitoring for infusion reactions has been compressed into a procedure that takes only minutes.
Why the IV-to-subcutaneous switch changes treatment access
The original intravenous formulation of daratumumab, marketed as DARZALEX, carries detailed prescribing requirements for slow infusion rates, dose-escalation schedules, and management of infusion-related reactions. Those requirements translate directly into chair time. A patient receiving the IV version occupies a clinic seat, nursing attention, and pharmacy resources for a large portion of the day, especially during early treatment cycles. For community oncology practices that operate with fewer infusion chairs than large academic medical centers, that bottleneck limits how many patients can be treated per day.
The subcutaneous formulation sidesteps much of that burden. The National Cancer Institute explains that hyaluronidase is the enabling ingredient: it temporarily loosens tissue under the skin so daratumumab can be absorbed after a simple injection rather than a prolonged drip. That mechanical change has downstream effects on scheduling, staffing, and patient willingness to continue therapy.
A reasonable hypothesis, though one not yet confirmed by published claims-linked registry data, is that the shorter administration time will correlate with higher treatment completion rates in community settings compared with academic centers. Community practices face tighter resource constraints, so freeing up infusion chairs could allow more patients to stay on schedule. Confirming or refuting that idea will require follow-up studies linking insurance claims to treatment adherence records, a dataset that does not yet appear in the public trial literature.
COLUMBA trial results and regulatory expansion
The case for switching formulations rests heavily on a single large trial and its regulatory aftermath. COLUMBA, a phase 3, randomized, non-inferiority study, enrolled patients with relapsed or refractory multiple myeloma and compared subcutaneous daratumumab plus hyaluronidase with the original IV formulation. Its prespecified primary endpoints were overall response rate and pharmacokinetic trough concentration, two measures designed to show that the subcutaneous route delivers enough drug to produce the same clinical benefit as the IV route.
Results in Lancet Haematology, indexed on PubMed, confirmed non-inferiority on both endpoints: the subcutaneous arm matched the IV arm in tumor response, and drug levels in the blood met the prespecified threshold. The European Medicines Agency and the U.S. Food and Drug Administration each reviewed these data and concluded that daratumumab given by injection under the skin was no less effective than IV infusion, opening the door to broader use.
Regulators subsequently extended the subcutaneous formulation’s reach beyond relapsed disease. In the United States, daratumumab and hyaluronidase was cleared in combination regimens for newly diagnosed multiple myeloma, broadening the patient population eligible for the quicker injection. That shift moved the subcutaneous version from a convenience alternative for pretreated patients to a front-line option that oncologists can offer at the start of therapy.
The original IV formulation remains available, and its detailed dosing and safety instructions are laid out in the official prescribing information. Clinicians who initiated patients on IV daratumumab before the subcutaneous version became accessible have had to weigh the logistics of switching mid-course-such as insurance coverage, scheduling, and patient preference-against the clear benefits of shorter visits and reduced infusion-related reactions.
Both formulations share certain hematology and transfusion-medicine complexities. Daratumumab targets CD38 on myeloma cells but also binds to CD38 on red blood cells, interfering with standard blood bank compatibility testing. This effect, documented in the transfusion literature, requires coordination between oncology teams and transfusion services to ensure that patients can receive safe blood products during treatment.
Gaps in long-term and real-world evidence
Several important questions remain open. COLUMBA demonstrated equivalent response rates and drug levels, but long-term overall survival data directly comparing subcutaneous and IV daratumumab are still limited in the public domain. The trial was powered to establish non-inferiority on short- to medium-term endpoints rather than to detect subtle differences in survival curves over many years.
Moreover, the highly controlled environment of a phase 3 study does not fully capture what happens in routine oncology practice. In COLUMBA, adherence was closely monitored, visit schedules were standardized, and patients met strict eligibility criteria. Community clinics, by contrast, care for older individuals with more comorbidities, transportation barriers, and insurance constraints that can disrupt treatment schedules. Whether the convenience of a brief injection leads to better long-term adherence-and ultimately better outcomes-in these real-world populations remains to be systematically studied.
Safety data also warrant ongoing surveillance. The trial and early post-marketing reports suggest that subcutaneous administration may reduce the incidence and severity of infusion-related reactions compared with IV dosing, likely because the injection delivers the drug more slowly into the systemic circulation. However, rare adverse events may only become apparent after many thousands of patients have been treated outside of clinical trials. Pharmacovigilance databases and registry studies will be essential to detect any unexpected safety signals unique to the subcutaneous formulation or to specific patient subgroups.
Another area of uncertainty involves health economics. Shorter administration times intuitively free up infusion chairs and nursing resources, but the net financial impact on clinics and health systems depends on reimbursement structures, drug acquisition costs, and staffing models. Some centers may realize substantial efficiency gains, while others may see a more modest effect if they are already operating below capacity. Robust cost-effectiveness analyses that incorporate patient time, caregiver burden, and system-level resource use are still emerging.
Implications for patients and providers
For patients, the most immediate benefit of subcutaneous daratumumab is less time in the clinic. Instead of planning an entire day around an infusion, many individuals can receive treatment in a single brief visit. This change can reduce travel fatigue, scheduling conflicts with work or caregiving responsibilities, and the psychological weight of prolonged chair time. It may also make it easier for patients who live far from major cancer centers to receive care closer to home in community settings.
For providers, the shift creates flexibility but also new decisions. Oncologists must determine which patients are best suited for subcutaneous administration, taking into account prior reactions, body habitus, and comorbidities. Nurses need training in proper injection technique, recognition of local injection-site reactions, and counseling about what patients should expect after leaving the clinic. Pharmacists must adjust workflows for drug preparation and storage, ensuring that both formulations are available when needed.
Communication with patients remains central. Some individuals may feel anxious about changing a regimen that appears to be working, even if the evidence supports equivalence. Others may have concerns about injection discomfort or about receiving a newer formulation. Clear explanations of the data, including what is known and what is still being studied, can help patients participate meaningfully in decisions about their care.
Looking ahead
The transition of daratumumab from IV infusion to subcutaneous injection illustrates a broader trend in oncology: re-engineering existing therapies to be more compatible with patients’ lives and with the realities of modern cancer clinics. As more biologic drugs are reformulated for subcutaneous delivery, questions raised by the daratumumab experience-about long-term outcomes, real-world adherence, safety, and cost-will recur.
Future research linking clinical records, claims data, and patient-reported outcomes will be critical to determine whether the practical advantages of shorter visits translate into measurable gains in survival, quality of life, or both. Until those data mature, the available evidence supports subcutaneous daratumumab as a clinically comparable, logistically simpler alternative to IV infusion, offering patients and providers another way to tailor myeloma treatment to individual needs and circumstances.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
